Back to Results
First PageMeta Content
Antiemetics / Abdominal pain / General practice / Syndromes / Ketones / Irritable bowel syndrome / Diarrhea / Ramosetron / 5-HT3 antagonist / Medicine / Health / Gastroenterology


Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella
Add to Reading List

Document Date: 2015-05-26 01:47:13

Open Document

File Size: 73,81 KB

Share Result on Facebook

City

Tokyo / /

Company

Astellas Pharma Inc. / /

Country

Japan / /

Event

FDA Phase / Product Release / /

/

IndustryTerm

Treatment of Diarrhea / /

MedicalCondition

Diarrhea-predominant Irritable Bowel Syndrome / visceral hypersensitivity / abdominal pain / pain / organic disorder / disease / diarrhea / constipation / irritable bowel syndrome / /

Organization

Ministry of Health / /

Person

Yoshihiko Hatanaka / /

/

Position

President and CEO / /

Product

Irribow®/Irribow® OD tablets / OD Tablets / Irribow / Irribow® / Irribow®/Irribow® OD / Irribow® Tablets / /

URL

http /

SocialTag